New video on ADCC assays from BioOutsource
Rapidly reveals the factors to consider when using ADCC assays for producing precise biosimilar comparability data.
Sartorius Stedim Biotech (SSB) BioOutsource has announced a new video is now available on-line explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the factors affecting the use of ADCC assays and discusses what to consider when determining comparability and designing biosimilar drugs.
In just five minutes, bioassay development experts, Dr Catriona Thomson and Dr Daniel Galbraith describe in this engaging video the challenges of using ADCC assays and explain when to use the different types of assay to assess biosimilars.
Dr Thomson lists four key reasons why ADCC activity is the greatest road-block to achieving approval of biosimilars and, with real ADCC assay data, shows what a biosimilar which has poor comparability to the innovator molecule looks like.
Dr Daniel Galbraith then rapidly reveals the science behind ADCC assays and describes with real data how different types of effector cell can dramatically affect biological relevance and sensitivity. This provides scientists with a quick snap-shot as to what ADCC assay format is most relevant for the current stage of their biosimilar’s development.
In short, the video offers researchers an excellent resource that they can view on their smartphone, tablet or computer of factors to consider when using ADCC assays for an accurate comparison of biosimilars to innovator molecules.
To access the informative video, go to: https://ow.ly/UvNBj
Dr Daniel Galbraith, Chief Scientific Officer of BioOutsource commented: “Having a biosimilar and an innovator molecule with different ADCC activity can result in costly changes to the manufacturing process and delays with regulatory approval. It is therefore vital to understand at the earliest stage of development the types of ADCC assay available to prove comparability.”
Galbraith continued: “We’re delighted to make this new video available as it explains in simple terms some of the complicated technical factors that affect how an ADCC assay will perform. Scientists that watch the video will have a better understanding of ADCC assays and this will help guide them to methodologies for developing biosimilars with fingerprint like similarity to the innovator molecule.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.